New Drug Approved for Early Alzheimer’s
The New York Times
The drug, Kisunla, made by Eli Lilly, is the latest in a new class of treatments that could modestly slow cognitive decline in initial stages of the disease but also carry safety risks.
The Food and Drug Administration on Tuesday approved a new drug for Alzheimer’s disease, the latest in a novel class of treatments that has been greeted with hope, disappointment and skepticism.
The drug, donanemab, to be sold under the brand name Kisunla, was shown in studies to modestly slow the pace of cognitive decline in early stages of the disease. It also had significant safety risks, including swelling and bleeding in the brain.
Kisunla, made by Eli Lilly, is similar to another drug, Leqembi, approved last year. Both are intravenous infusions that attack a protein involved in Alzheimer’s, and both can slow the unfolding of dementia by several months. Both also carry similar safety risks. Leqembi, made by Eisai and Biogen, is given every two weeks; Kisunla is given monthly.
Kisunla has a significant difference that may appeal to patients, doctors and insurers: Lilly says patients can stop the drug after it clears the protein, amyloid, which clumps into plaques in the brains of people with Alzheimer’s.
“Once you’ve removed the target that you’re going after, you then can stop dosing,” said Anne White, an executive vice president of Lilly and president of its neuroscience division. She said that this could reduce the overall cost and inconvenience of the treatment as well as the risk of side effects.
The company said that 17 percent of patients receiving donanemab in the 18-month-long clinical trial were able to discontinue the drug at six months, 47 percent stopped within a year and 69 percent stopped within 18 months. Their cognitive decline continued to slow even after they stopped. The company is evaluating how long that slowing will continue past the duration of the trial, said Dr. John Sims, a medical director at Lilly.
A review of the betting market’s social media feeds found it has published hundreds of false and misleading posts.
Gerd Faltings proved a conjecture that had been unsolved for six decades, using connections between numbers and geometry.
The reality star who rose to fame on “The Secret Lives of Mormon Wives” is being investigated for domestic violence along with the father of one of her children.
A new study found that women who went through so-called premature menopause had 40 percent more fatal and nonfatal heart attacks over the course of their lives.
In a stroke of luck, astronomers saw the comet C/2025 K1 (ATLAS) break into four or five fragments in November after it passed close to the sun.
New A.I. bots can do more than just chat. They can edit files, send emails, book trips and cause trouble.
The series, “inspired” by the story of a royal dresser later convicted of murder, is getting added attention over the former Duchess of York’s ties to Jeffrey Epstein.
Lawyers for both sides in the federal lawsuit, brought by six medical organizations, are trying to understand the ramifications of the judge’s decision.
Andy Weir discusses his science-fueled novel “Project Hail Mary,” which has been adapted into a film that opens in theaters on Friday.
After years of criticism and financial risk, Palantir, Anthropic and small start-ups are generating rewards from their investments in defense tech.
In a legal filing, the government said it questioned whether the A.I. start-up could be a “trusted partner” in wartime, which led it to label the company a supply chain risk.
Before humanity sent satellites, telescopes, humans and weapons into space, Robert Goddard experimented with the first liquid-fueled rocket on his aunt’s farm.
A draft State Department memo outlines ways the Trump administration may ratchet up pressure on the African country by ending health support “on a massive scale.”